FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

BP Haynes

Research Profile

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
BP Haynes; Nicole Rotmensz; Ian E Smith; Giuseppe Viale; Roger A'Hern; Viviana Galimberti; Bianca Gibelli; Mitch Dowsett
Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer.
H Anderson; Roger A'Hern; BP Haynes; Margaret Hills; A F Leary; Ian E Smith; Lila Zabaglo; Mitch Dowsett
Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
BP Haynes; Anne Hege Straume; Jürgen Geisler; Roger A'Hern; Hildegunn Helle; Ian E Smith; Per E Lønning; Mitch Dowsett
Intratumoral estrogen disposition in breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of BP Haynes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: BP Haynes; Nicole Rotmensz; Ian E Smith; Giuseppe Viale; Roger A'Hern; Viviana Galimberti; Bianca Gibelli; Mitch Dowsett
Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer.
Breast cancer research and treatment 2013;138(1):157-65.
2011: H Anderson; Roger A'Hern; BP Haynes; Margaret Hills; A F Leary; Ian E Smith; Lila Zabaglo; Mitch Dowsett
Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(8):1770-6.
2010: BP Haynes; Anne Hege Straume; Jürgen Geisler; Roger A'Hern; Hildegunn Helle; Ian E Smith; Per E Lønning; Mitch Dowsett
Intratumoral estrogen disposition in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1790-801.
2004: Stephen R D Johnston; Lindsey Gumbrell; T R J Evans; R E Coleman; IE Smith; C J Twelves; M Soukop; D W Rea; Helena Earl; A Howell; A Jones; PA Canney; T J Powles; BP Haynes; Bernard P Nutley; RM Grimshaw; Michael Jarman; Gavin Halbert; M Brampton; J Haviland; Mitch Dowsett; R Charles Coombes
A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.
Cancer chemotherapy and pharmacology 2004;53(4):341-8.
2003: BP Haynes; Mitch Dowsett; W R Miller; J M Dixon; A S Bhatnagar
The pharmacology of letrozole.
The Journal of steroid biochemistry and molecular biology 2003;87(1):35-45.
1999: Stephen R D Johnston; Irene Boeddinghaus; S Riddler; BP Haynes; IR Hardcastle; Martin G Rowlands; RM Grimshaw; Michael Jarman; Mitch Dowsett
Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Cancer research 1999;59(15):3646-51.
1997: S E Barrie; BP Haynes; G A Potter; F C Chan; Phyllis M Goddard; Mitch Dowsett; Michael Jarman
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors.
The Journal of steroid biochemistry and molecular biology 1997;60(5-6):347-51.
1997: Stephen R D Johnston; S Riddler; BP Haynes; R A'Hern; IE Smith; Michael Jarman; Mitch Dowsett
The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
British journal of cancer 1997;75(6):804-9.
1996: F C Chan; G A Potter; S E Barrie; BP Haynes; Martin G Rowlands; J Houghton; Michael Jarman
3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer.
Journal of medicinal chemistry 1996;39(17):3319-23.
1995: H Young; Paul Carnochan; M Trivedi; G A Potter; S A Eccles; BP Haynes; Michael Jarman; Robert J Ott
Pharmacokinetics and biodistribution of radiolabelled idoxifene: prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy.
Nuclear medicine and biology 1995;22(4):405-11.
1995: R Charles Coombes; BP Haynes; Mitch Dowsett; M Quigley; J English; I R Judson; L J Griggs; G A Potter; R McCague; Michael Jarman
Idoxifene: report of a phase I study in patients with metastatic breast cancer.
Cancer research 1995;55(5):1070-4.
1994: S E Barrie; G A Potter; Phyllis M Goddard; BP Haynes; Mitch Dowsett; Michael Jarman
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).
The Journal of steroid biochemistry and molecular biology 1994;50(5-6):267-73.
1993: Stephen R D Johnston; BP Haynes; Ian E Smith; Michael Jarman; N P Sacks; S R Ebbs; Mitch Dowsett
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.
Lancet 1993;342(8886-8887):1521-2.
1993: Stephen R D Johnston; BP Haynes; N P Sacks; J A McKinna; L J Griggs; Michael Jarman; Michael Baum; Ian E Smith; Mitch Dowsett
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.
Breast cancer research and treatment 1993;28(3):241-50.
1991: BP Haynes; Michael Jarman; Mitch Dowsett; A Mehta; P E Lønning; L J Griggs; A Jones; T Powles; R Stein; R Charles Coombes
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.
Cancer chemotherapy and pharmacology 1991;27(5):367-72.
1990: R McCague; I B Parr; BP Haynes
Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites.
Biochemical pharmacology 1990;40(10):2277-83.